Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
p-HER2apt-siMED1 RNA nanoparticles
- Development stage
- Preclinical
- Lead developer
- RNA Nanotherapeutics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
p-HER2apt-siMED1 RNA nanoparticles is a preclinical-stage multifunctional RNA nanoparticle therapeutic developed by RNA Nanotherapeutics (a spinout from the University of Cincinnati) for the treatment of HER2-overexpressing, therapy-resistant breast cancer. Built on a phi29 bacteriophage packaging RNA (pRNA) three-way junction (3WJ) scaffold, the nanoparticle is designed for targeted delivery. It incorporates a HER2-targeting RNA aptamer (p-HER2apt) to selectively bind and internalize into HER2-positive breast cancer cells, and carries two small interfering RNA (siRNA) payloads targeting Mediator Subunit 1 (MED1). MED1 is a transcription coactivator co-amplified with HER2 that drives tumor progression, metastasis, and resistance to endocrine therapies (such as tamoxifen). By silencing MED1, the nanoparticles reduce tumor burden, inhibit cancer stem cell formation, and reverse therapeutic resistance.
- Other names
- p-HER2apt-siMED1p-HER-2apt-siMED1p-HER 2apt-siMED1pRNA-HER2apt-siMED1pRNA-HER-2apt-siMED1pRNA-HER 2apt-siMED1pRNA-HER2apt-siMED1 nanoparticlespRNA-HER-2apt-siMED1 nanoparticlespRNA-HER 2apt-siMED1 nanoparticlespRNA-HER2apt-siMED1 RNA nanoparticlespRNA-HER-2apt-siMED1 RNA nanoparticlespRNA-HER 2apt-siMED1 RNA nanoparticles
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)Mediator complex subunit 1 mRNA (MED1 mRNA)
Beyond the preview
Go deeper on p-HER2apt-siMED1 RNA nanoparticles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on p-HER2apt-siMED1 RNA nanoparticles.